Project Grant HT9425261E256
- Federal Project Grant Award Summary The University of Texas Southwestern Medical Center received a $1,062,400 project grant award from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) effective November 1, 2025, through October 31, 2029. The award supports research to identify NEK5 as a hidden driver in kidney cancer, advancing biomedical innovations relevant to military health priorities and public health objectives. As a leading academic...
- Federal Grant Award Summary The University of Texas Southwestern Medical Center received a $323,700 project grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), effective November 1, 2025, through October 31, 2028. This award supports research utilizing enhancer CRISPR screening to identify PLXNA1 as a critical regulator in clear cell renal cell carcinoma (ccRCC). The research represents a translational science initiative aligned...
- Federal Project Grant Award Summary The University of Texas Southwestern Medical Center received a $319,800 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), effective November 1, 2025, through October 31, 2028. The award funds research on novel hypoxia-inducible factor 2 (HIF-2) regulators and therapeutic targets for kidney cancer, conducted at the institution's Dallas, Texas campus. This research initiative...
- Federal Project Grant Award Summary The University of Texas Southwestern Medical Center received a $1,311,922 project grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) with an award date of September 1, 2025, and completion date of August 31, 2028. The project, titled "Next-Generation RCC Mouse Models Reproducing Human Oncogenotypes to Advance Therapeutics," supports biomedical research focused on developing advanced...
- Federal Grant Award Summary The University of Texas Southwestern Medical Center received a $1.476 million Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), awarded on August 15, 2025, with a completion date of August 14, 2028. This award supports the development and research of an in situ tumor vaccine designed to stimulate antitumor immunity against breast cancer. The three-year project will be conducted at UT...
- Federal Project Grant Award Summary The University of Texas Southwestern Medical Center received a $319,693 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420), effective May 1, 2025 through July 31, 2027. The award supports research focused on dissecting the mechanism of selective HIF-2 regulation of PTHRP and hypercalcemia in clear cell renal carcinoma. This biomedical research project aims to advance understanding of...
- Federal Project Grant Award Summary The University of Texas Southwestern Medical Center received a $1,049,994 project grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) for the period June 1, 2026 through May 31, 2029. The award supports research investigating the therapeutic potential of detecting and inhibiting cytosolic adenosine diphosphate (ADP)-ribosylation as a novel treatment approach in ovarian cancer. This research...
- Summary of Federal Grant Award The University of Texas Southwestern Medical Center (UT Southwestern) received a $1.23 million Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) for a four-year period beginning August 1, 2025 and concluding July 31, 2029. The award supports research focused on "Imaging Strategies and Biomarkers for Detecting the Metabolic Interplay of Glutamine and Aspartate in Renal Cell Carcinoma...
- Federal Project Grant Award Summary The University of Texas Southwestern Medical Center received a $1.65 million project grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) effective April 1, 2026, through March 31, 2029. The award supports research focused on targeting cyclin-dependent kinase 4/6 (CDK4/6) inhibitor resistance in patients with estrogen receptor-positive (ER+) breast cancer. This three-year initiative represents the...
- Federal Grant Award Summary The University of Texas Southwestern Medical Center received a $450,174 Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) for the period September 1, 2025, through August 31, 2030. This award, titled "Building on the Foundation of the Academy of Kidney Cancer Investigators," supports biomedical research initiatives focused on kidney cancer investigation. The Military Medical...
The University of Texas Southwestern Medical Center received a $1.7 million Project Grant from the Defense Health Agency (DHA) under the Military Medical Research and Development program (CFDA 12.420) to conduct research on mapping, characterizing, and elucidating the clinical relevance of driver enhancers in lethal prostate cancer. The three-year award, effective June 15, 2026 through June 14, 2029, funds hypothesis-driven biomedical research designed to advance innovative medical solutions for critical health challenges. This project represents the DHA's investment in translational cancer research that bridges basic science discoveries to clinical applications, aligning with the Military Medical Research and Development program's mission to transform healthcare through impactful research initiatives. Under this award, UT Southwestern will deliver research and development services focused on prostate cancer investigation, including biomarker discovery, translational research activities, and clinical advancement of findings. The research conducted at the Dallas, Texas location will contribute to the broader federal effort to identify and validate driver enhancers in aggressive prostate cancer, potentially yielding therapeutic targets and improved clinical outcomes. This award reflects UT Southwestern's established capacity as a leading academic research institution with demonstrated expertise in conducting federally-funded cancer research and translational investigations across multiple therapeutic domains.Federal Project Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $1.7m | 6/14/26 |